What MEDRx does

MEDRx Co., Ltd. (株式会社メドレックス, Tokyo Stock Exchange Growth Market: 4586) is a Japanese pharmaceutical formulation development company founded in January 2002 in Kagawa Prefecture, Japan. The company develops novel transdermal medicines built on three proprietary drug delivery platforms: ILTS® (Ionic Liquid Transdermal System), which uses ionic liquids to dramatically improve skin permeability of active pharmaceutical ingredients and is described as the world's first application of ionic liquid technology to pharmaceutical preparations; NCTS® (Nano-sized Colloid Transdermal System), which uses nano-scale colloids to enhance skin absorption and reduce skin-side effects; and Microneedle Array Patch (MAP), a biodegradable resin-based painless delivery system for vaccines, nucleic acid medicines, and protein drugs. The company's pipeline comprises five named transdermal patch programs — MRX-4TZT (tizanidine for muscle spasticity), MRX-5LBT (lidocaine for post-herpetic neuralgia), MRX-6LDT (diclofenac/lidocaine for chronic pain), MRX-7MLL (memantine for Alzheimer's disease), and MRX-9FLT (abuse-deterrent fentanyl for severe pain) — targeting a combined addressable market that includes approximately ¥2.3 trillion (US muscle relaxants), ¥640 billion (US chronic pain), ¥520 billion (US Alzheimer's), and ¥240 billion (US fentanyl) as of 2024.

The business model centers on licensing the ILTS®/NCTS®/MAP platforms and developing pipeline assets to commercialization via co-development partners and sales licensees in target geographies. MRX-5LBT, the lead asset, received FDA marketing approval in September 2025 on its fourth application cycle (after CRLs in 2021, 2023, 2024), with US launch planned for H1 2026 via negotiated sales partners and co-developed with DWTI under a 2020 agreement that includes milestone payments of up to ¥200 million plus ongoing royalties on US revenue. MRX-9FLT carries FDA Fast Track Designation (July 2021), and MRX-7MLL cleared IND in October 2024. The sole currently marketed product is Iodocoat Ointment 0.9%, launched in August 2005 for pressure ulcer and skin ulcer treatment in Japan. Revenue is generated from a mix of pharmaceutical product sales, partner milestone payments, and royalty streams. The company operates through wholly-owned subsidiaries MEDRx USA INC. (Irvine, California, est. April 2015) and MEDRx Australia Pty Ltd (Melbourne, est. March 2024), and is led by a founder-family-led management team — President & CEO Matsumura Yonehiro (松村米浩) and Chairman Matsumura Shinra (松村眞良).

Name

MEDRx

Legal name

MEDRx Co., Ltd.

Website

https://medrx.co.jp

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

MEDRx (TYO: 4586) is a Japanese pharmaceutical formulation development company founded in 2002 that creates novel transdermal medicines using proprietary ILTS®, NCTS®, and microneedle array drug delivery platforms, with a five-asset pipeline targeting chronic pain, neuropathic pain, muscle spasticity, Alzheimer's, and opioid abuse.

Ownership category

akta.pro rank

Product category

Transdermal Pharmaceutical Products

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Transdermal drug delivery
• Pharmaceutical formulation
• Ionic liquid technology
• Transdermal patches
• Microneedle array systems

Headquarters

HQ city

Kagawa

HQ country

Japan

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue from sales of approved pharmaceutical products developed using proprietary transdermal technologies. MRX-5LBT received FDA approval in September 2025 with planned US market launch in first half of 2026.
2. Licensing and Milestone Payments: MEDRx receives milestone payments from partners upon achievement of development and regulatory milestones. DWTI partnership includes milestone payments up to 200 million JPY plus ongoing royalty payments based on US revenues.
3. Peak Sales Projections: MRX-4TZT projected peak sales of 300-1,000 million USD (approximately 450-1,500 billion JPY) based on market penetration of 9-30% of tizanidine oral market.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels3 records

Core offering

MEDRx is a pharmaceutical formulation development company that creates novel transdermal medicines using proprietary drug delivery technologies (ILTS®, NCTS®, and Microneedle Array Patch). It applies these platforms to develop and commercialize transdermal patches and ointments across pain management, muscle relaxation, Alzheimer's disease, and abuse-deterrent opioid indications, with its first FDA-approved product (MRX-5LBT lidocaine patch) cleared in September 2025 and its currently sold product being Iodocoat Ointment 0.9% in Japan.

Product overview

MEDRx (株式会社メドレックス) is a pharmaceutical formulation development company that creates novel transdermal medicines using proprietary drug delivery technologies. The company operates a platform-based business model centered on three core technology platforms: ILTS® (Ionic Liquid Transdermal System) for enhanced skin permeability, NCTS® (Nano-sized Colloid Transdermal System) for improved absorption and reduced side effects, and Microneedle Array for painless vaccine and biologic delivery. The technology platforms are applied across a pipeline of five named transdermal patch products targeting muscle relaxation, neuropathic pain, opioid abuse deterrence, Alzheimer's disease, and chronic pain. The company went public on the Tokyo Stock Exchange Mothers market in 2013 (now Growth Market) with stock code 4586, and has subsidiaries in the USA and Australia. The sole commercialized product is Iodocoat Ointment 0.9%, with MRX-5LBT newly approved in September 2025 and expected to launch in H1 2026.

Differentiator

Problem solved

Functional benefit

Brands

• ILTS®: Ionic Liquid Transdermal System - proprietary transdermal drug delivery technology using ionic liquids to dramatically improve skin permeability of active pharmaceutical ingredients.
• NCTS®
• Microneedle Array (MAP)

Products and services

• ILTS® (Ionic Liquid Transdermal System) Proprietary transdermal formulation technology platform that uses ionic liquids to dramatically improve skin permeability of active pharmaceutical ingredients, enabling drugs with poor solubility or weak absorbability to be delivered transdermally. Applied across MEDRx's pipeline.
• NCTS® (Nano-sized Colloid Transdermal System) Proprietary transdermal drug delivery technology platform using nano-sized colloids to increase skin absorption of active ingredients and reduce skin side effects.
• Microneedle Array Patch (MAP) Biodegradable resin-based microneedle patch system for painless transdermal delivery of vaccines, nucleic acid medicines, and protein medicines, enabling self-administration and room-temperature storage/transport.
• MRX-4TZT (Tizanidine Transdermal Patch) Pipeline product: tizanidine (central-acting muscle relaxant) formulated as a transdermal patch using ILTS® technology, intended for muscle spasticity and pain-associated conditions including neck/shoulder pain, lower back pain, frozen shoulder, and tension headache, with reduced drowsiness side effects versus oral tizanidine.
• MRX-5LBT (Lidocaine Transdermal Patch) FDA-approved lidocaine transdermal patch for post-herpetic neuralgia and neuropathic pain, differentiated from Lidoderm® by requiring approximately 30% less lidocaine while delivering superior skin gentleness, adhesion, and maintained adhesiveness during movement.
• MRX-9FLT (Abuse-Deterrent Fentanyl Transdermal Patch) Pipeline product: fentanyl transdermal patch with proprietary abuse-deterrent technology intended to prevent accidental pediatric exposure and misuse, targeting the severe/cancer pain market.
• MRX-7MLL (Memantine Transdermal Patch) Pipeline product: memantine transdermal patch for Alzheimer's disease using ILTS® technology to enable 3-day or 7-day dosing, improving compliance and quality of life versus three-times-daily oral memantine.
• MRX-6LDT (Diclofenac/Lidocaine Combination Transdermal Patch) Pipeline product: chronic pain treatment combining diclofenac and lidocaine in a single transdermal patch using ILTS® technology, positioned as a non-opioid alternative for the chronic pain market.
• Iodocoat Ointment 0.9% (ヨードコート軟膏0.9%) Currently commercialized pharmaceutical product: iodine-based topical ointment (0.9%) for treatment of pressure ulcers and skin ulcers, distributed through Japanese pharmaceutical channels.

Quantifiable outcome

• MRX-5LBT achieves equivalent efficacy with 30% less lidocaine compared to Lidoderm®
• +4 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• DWTI (De-Western Therapy Institute)coreStrategic or Co-development Partner · 1 April 2020Joint development agreement for MRX-5LBT in US market signed April 2020. DWTI provides milestone payments up to 200 million JPY and receives ongoing royalty payments based on US revenues. MEDRx retains primary responsibility for development and regulatory activities.

Scale indicators7 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• BioDelivery Sciences International: Specialty pharmaceutical company focused on pain management using novel drug delivery technologies, including the Bunavail buccal film and Belbuca patch. Directly comparable as a small-cap pain-focused specialty pharma with proprietary delivery technology.
• Zosano Pharma: Clinical-stage specialty pharmaceutical company developing microneedle patch delivery of biologics and small molecules. Directly comparable to MEDRx's Microneedle Array Patch (MAP) platform with similar transdermal biologics delivery thesis.
• LTS Lohmann Therapie-Systeme: German leader in transdermal therapeutic systems and oral thin films. Comparable as a pure-play transdermal drug delivery technology company serving global pharmaceutical partners with patch development and manufacturing capabilities.
• Hisamitsu Pharmaceutical: Japanese pharmaceutical company and global leader in transdermal patches (e.g., Salonpas®). Directly comparable as a Japanese pharma with proprietary transdermal drug delivery technology serving overlapping therapeutic areas including pain management.
• Teikoku Seiyaku: Japanese specialty pharmaceutical company focused on transdermal drug delivery systems. Comparable to MEDRx as a Japan-based transdermal patch developer with similar formulation technology focus and US-market ambitions.
• Aquestive Therapeutics: Specialty pharmaceutical company focused on complex drug delivery via oral films, sublingual, and transdermal routes. Comparable as a small-cap pharma developing proprietary delivery technologies for CNS and pain indications with partner-based commercialization.
• Noven Pharmaceuticals: US specialty pharmaceutical company specializing in transdermal drug delivery, known for Vivelle-Dot and other patch products (acquired by Hisamitsu in 2009). Directly comparable as a transdermal-focused formulation specialist targeting the same US pain and CNS markets as MEDRx.

Broad incumbents

• Nitto Denko: Diversified Japanese materials and life sciences company with significant transdermal drug delivery operations. Comparable as a Japan-headquartered company with proprietary transdermal patch technology and global pharmaceutical presence, but operating at materially larger scale.
• Corium (Gurnet Point Capital): US commercial-stage biopharmaceutical company with proprietary transdermal drug delivery platform (e.g., Adlarity, Corplex). Comparable as a transdermal CNS/pain specialist but broader portfolio and larger commercial scale than MEDRx.

Emerging players

• Dermavant Sciences: Clinical-stage biopharmaceutical company developing novel therapies in immuno-dermatology via topical delivery (Vtama®). Comparable as a smaller specialty pharma leveraging proprietary topical/transdermal delivery in a defined therapeutic niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MEDRx